Overall, engineered APCs in the presence of tumor antigens enabled the substantial expansion of neoantigen (and TAA)-specific CD8 T cells in melanoma and in ovarian, lung and colon cancer, thus establishing a highly sensitive and reproducible methodology to identifying tumor antigens. The gene discussed is CD8A; the disease is neoplasm.